biotech insider buying
biotech insider buying Articles
The most notable insider purchases of the past week came from return buyers, including Warren Buffett. Another biotech IPO also tempted insiders to scoop up some shares.
Published:
Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and initial and secondary offerings tempted other insiders.
Published:
With the earnings-reporting season underway, insider buying has been slow. Yet some return buyers continue to build stakes, including huge new purchases in the past week.
Published:
The number of notable insider purchases has slowed since the beginning of the year. Yet one huge buy in the past week stood out.
Published:
Berkshire Hathaway came back this past week to load up on one particular tech stock. Meanwhile, other insiders were acquiring shares of a pair of biotech stocks.
Published:
Warren Buffett has been trimming stakes lately. So it was a bit of a surprise to see three huge insider purchases from Berkshire Hathaway late last week.
Published:
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
Published:
The past week brought some huge insider share purchases, including a contrarian buy at an e-commerce platform operator and another at a troubled satellite provider.
Published:
Warren Buffett again boosted his stake in the newly independent Sirius XM. A biotech IPO prompted huge insider buying as well.
Published:
Warren Buffett again boosted his stake in the newly independent Sirius XM. Biotech stocks continue to prompt notable insider buying as well.
Published:
Warren Buffett recently boosted his stake in the newly independent Sirius XM. Biotech initial public offerings in the past week also prompted some huge insider buying.
Published:
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Published:
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
Published:
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Published:
Though insider buying has slowed to a trickle in the past two weeks, two CEOs and two beneficial owners made notable purchases.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.